Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Backs Out Of Hemophilia, But Who Benefits?

Executive Summary

With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.


Related Content

Biopharma Quarterly Dealmaking Statistics, Q2 2016
Start-Up Quarterly Statistics, Q2 2016
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Sobi On The Look-Out For Licensing, M&A Opportunities
Biogen Shores Up Gene Therapy Ambitions With New Deal
Biogen Backs Down From M&A
Rumor Has It: Can Biogen Find A Buyer For Hemophilia Drugs?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts